Valneva (NASDAQ:VALN) Shares Gap Down – Here’s Why

Valneva SE (NASDAQ:VALN) shares gapped down before the market opened on Monday . The stock had previously closed at $7.26, but opened at $6.80. Valneva shares last traded at $6.74, with a volume of 11,066 shares.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on VALN shares. Guggenheim reduced their price objective on shares of Valneva from $17.00 to $15.00 and set a “buy” rating for the company in a report on Monday, March 24th. HC Wainwright reiterated a “buy” rating and set a $17.00 price target on shares of Valneva in a research note on Monday.

Valneva Price Performance

The company has a current ratio of 2.78, a quick ratio of 2.25 and a debt-to-equity ratio of 0.70. The business has a 50-day moving average of $6.63 and a 200 day moving average of $5.59. The firm has a market capitalization of $554.12 million, a PE ratio of -52.45 and a beta of 1.93.

Valneva (NASDAQ:VALN) last announced its earnings results on Thursday, March 20th. The company reported ($0.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.32). The business had revenue of $56.48 million during the quarter, compared to analysts’ expectations of $55.64 million. Valneva had a negative return on equity of 3.93% and a negative net margin of 4.35%. As a group, research analysts anticipate that Valneva SE will post 0.13 EPS for the current fiscal year.

Institutional Trading of Valneva

An institutional investor recently bought a new position in Valneva stock. ABC Arbitrage SA acquired a new stake in shares of Valneva SE (NASDAQ:VALN) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 19,244 shares of the company’s stock, valued at approximately $84,000. Hedge funds and other institutional investors own 11.39% of the company’s stock.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.